Calsequestrin

Acidic protein found in SARCOPLASMIC RETICULUM that binds calcium to the extent of 700-900 nmoles/mg. It plays the role of sequestering calcium transported to the interior of the intracellular vesicle.

Networked: 209 relevant articles (4 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Knollmann, Björn C: 12 articles (01/2018 - 09/2007)
2.	Volpe, Pompeo: 10 articles (01/2020 - 09/2003)
3.	Wall, Jack R: 10 articles (01/2012 - 10/2006)
4.	Arad, Michael: 9 articles (01/2020 - 07/2007)
5.	Györke, Sandor: 9 articles (01/2018 - 09/2003)
6.	Viatchenko-Karpinski, Serge: 9 articles (01/2012 - 09/2003)
7.	Terentyev, Dmitry: 9 articles (08/2008 - 09/2003)
8.	Priori, Silvia G: 8 articles (01/2018 - 03/2004)
9.	Eldar, Michael: 8 articles (01/2017 - 07/2007)
10.	Neumann, Joachim: 7 articles (06/2022 - 05/2007)

Related Diseases

1.	Heart Failure 01/01/2016 - "To examine whether PLN inhibition can improve survival rate as well as cardiac function in heart failure, we performed PLN ablation in calsequestrin overexpressing (CSQ-Tg) mice, a severe heart failure model, using clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) system. " 09/01/2011 - "A transgenic mouse overexpressing calsequestrin can be regarded as an animal model of heart failure. " 04/01/2011 - "To determine the functional role of PGC-1α in oxidative phenotype-associated protection, skeletal muscle-specific PGC-1α transgenic mice were crossbred with cardiac-specific calsequestrin transgenic mice, a genetic model of chronic heart failure. " 09/01/2010 - "As a model of heart failure, transgenic mice (TG) with selective overexpression of calsequestrin (CSQ) in the heart were used. " 03/25/2010 - "After chronic administration via a mini-osmotic pump (Alzet), some analogues significantly increased intact heart contractile function in calsequestrin-overexpressing mice (genetic model of heart failure) compared to vehicle-infused mice (all inactive at the vasodilatory P2Y(1) receptor). "
2.	Polymorphic catecholergic ventricular tachycardia 07/01/2007 - "Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism." 10/22/2020 - "CASQ2 gene variants associated with catecholaminergic polymorphic ventricular tachycardia (CPVT) in humans are positively correlated with a high degree of evolutionary conservation across all calsequestrin homologues. " 01/01/2020 - "Homozygous calsequestrin 2 (CASQ2) point mutations leads to catecholaminergic polymorphic ventricular tachycardia: a common pathogenetic feature appears to be the drastic reduction of mutant CASQ2 in spite of normal transcription. " 01/01/2020 - "Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants." 07/31/2019 - "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations of cardiac calsequestrin (CASQ2) that impair its characteristic ability of Ca2+-induced polymerization-depolymerization. "
3.	Graves Disease (Basedow Disease) 01/01/2009 - "In this study we have tested for T lymphocyte sensitization to calsequestrin in patients with Graves' disease, with and without orbitopathy, in standard proliferation assay. " 07/01/2006 - "Of these antigens, only calsequestrin is expressed more in eye muscle than other skeletal muscles, which could explain at least partly the specific involvement of eye muscle in patients with Graves' disease. " 10/01/2006 - "Prevalences of positive antibody tests to calsequestrin (75.0%) and collagen XIII (43.8%) were significantly greater in Graves' disease (GD) patients with ophthalmopathy than in healthy subjects, whereas modest significance was demonstrated with antibodies against Fp, but not G2s. " 01/01/1999 - "A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin." 07/01/2006 - "Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease."
4.	Tachycardia (Tachyarrhythmias) 11/01/2003 - "Mutations of two myocardial calcium signaling molecules, ryanodine receptor 2 (RYR2) and calsequestrin 2 (CASQ2), may cause catecholaminergic polymorphic ventricular tachycardia (CPVT), a severe inherited arrhythmic disease manifesting with salvoes of exercise-induced bidirectional and polymorphic tachycardias. " 01/01/2020 - "Lower calsequestrin 2 protein levels, faster diastolic depolarization (DD) and efficacy of JTV-519 (46% at 1 µmol/L) to terminate tachycardia indicate alterations of Ca2+ handling being part of the underlying mechanism. " 01/01/2005 - "Therefore, we have examined the previously reported trifluoperazine and other pharmaceuticals that have similar heart-related side effects (such as tachycardia; bradycardia; palpitation; changing PR, QRS, QTc intervals in electrocardiogram; heart failure) for their binding affinity to cardiac calsequestrin (cCSQ) using isothermal titration calorimetry. " 08/01/2004 - "These data reveal in tachycardia-induced heart failure a new and potentially important change in the mannose content of calsequestrin glycans, perhaps indicative of defective junctional SR trafficking and Ca2+ release complex assembly."
5.	Eye Diseases (Eye Disease) 10/01/2006 - "Significantly greater serum levels of antibodies against calsequestrin, G2s, and collagen XIII, but not Fp, were found in GD patients with ophthalmopathy compared to control patients without eye disease and healthy subjects. " 01/01/1999 - "wt. of 67 kDa. Serum antibodies against calsequestrin were found in 40% of patients with clinically active TAO, but in only 4% of those with stable eye disease, and in 5% of normal subjects, by immunoblotting. " 01/01/2012 - "In one patient with isolated congestive ophthalmopathy who was studied intensely, collagen XIII antibodies were initially positive and then became negative as the eye disease stabilized, while antibodies targeting calsequestrin were always negative. " 05/01/1998 - "Antibodies reactive with the parent protein, of which G2s is a fragment, may be markers of early eye muscle swelling and inflammation, whereas those reactive with the 64-kd protein and, less often, calsequestrin are associated with established eye disease. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)
3.	Antibodies
4.	Collagen
5.	Calmodulin (Calcium-Dependent Activator Protein)
6.	Flecainide (Tambocor)
7.	K201 compound
8.	1-(9-fluorenyl)ethyl chloroformate
9.	phospholamban
10.	Calcium-Binding Proteins

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation
3.	Ambulatory Care (Outpatient Care)